OVID
Ovid Therapeutics Inc
NASDAQ: OVID · HEALTHCARE · BIOTECHNOLOGY
$2.45
+8.41% today
Updated 2026-10-28
Market cap
$421.84M
P/E ratio
—
P/S ratio
266.48x
EPS (TTM)
$-0.22
Dividend yield
—
52W range
$1 – $3
Volume
1.7M
Ovid Therapeutics Inc (OVID) Insider transactions
Net insider activity
Net buying (19,273,574 shares)
Buy transactions
89
Sell transactions
11
All transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-06 | CARTER, CHARLES ROSS | Chief Financial Officer | Buy | 50,000 | — | — |
| 2026-06-15 | GREKA, ANNA | Director | Buy | 130,000 | — | — |
| 2026-04-07 | PAPADOPOULOS, STELIOS | Director | Buy | 17,578 | $2.56 | $44999.68 |
| 2026-04-07 | FRIEDMAN, BART | Director | Buy | 8,789 | $2.56 | $22499.84 |
| 2026-04-07 | FITZGERALD, KEVIN JOSEPH | Director | Buy | 17,578 | $2.56 | $44999.68 |
| 2026-03-23 | LEVIN, JEREMY M | Director, Executive Chairman | Sale | 47,333 | — | — |
| 2026-03-23 | LEVIN, JEREMY M | Director, Executive Chairman | Buy | 47,333 | $1.40 | $66266.20 |
| 2026-02-26 | RONA, JEFFREY A | CBFO | Buy | 408,750 | — | — |
| 2026-02-26 | RONA, JEFFREY A | CBFO | Buy | 68,125 | — | — |
| 2026-02-26 | PAPADOPOULOS, STELIOS | Director | Buy | 65,000 | — | — |
| 2026-02-26 | LEVIN, JEREMY M | Director | Buy | 957,000 | — | — |
| 2026-02-26 | FRIEDMAN, BART | Director | Buy | 65,000 | — | — |
| 2026-02-26 | FITZGERALD, KEVIN JOSEPH | Director | Buy | 65,000 | — | — |
| 2026-02-26 | DUNCAN, BARBARA GAYLE | Director | Buy | 65,000 | — | — |
| 2026-02-26 | BERNSTEIN, KAREN | Director | Buy | 65,000 | — | — |
| 2026-02-26 | ALEXANDER, MARGARET A. | Director, President and CEO | Buy | 1,435,000 | — | — |
| 2026-02-23 | RONA, JEFFREY A | CBFO | Sale | 8,541 | $1.45 | $12384.45 |
| 2026-02-23 | ALEXANDER, MARGARET A. | Director, President and CEO | Sale | 11,656 | $1.45 | $16901.20 |
| 2026-01-04 | ALEXANDER, MARGARET A. | Director, President and CEO | Buy | 890,000 | — | — |
| 2025-12-15 | LEVIN, JEREMY M | Director, CEO | Sale | 71 | — | — |
| 2025-12-15 | LEVIN, JEREMY M | Director, CEO | Buy | 71,000 | — | — |
| 2025-12-11 | LEVIN, JEREMY M | Director, CEO | Buy | 35,500 | — | — |
| 2025-12-11 | LEVIN, JEREMY M | Director, CEO | Buy | 71 | — | — |
| 2025-12-11 | LEVIN, JEREMY M | Director, CEO | Buy | 47,333 | — | — |
| 2025-12-08 | TAKEDA, PHARMACEUTICAL CO LTD | 10% Owner | Sale | 1,250 | — | — |
| 2025-12-08 | TAKEDA, PHARMACEUTICAL CO LTD | 10% Owner | Buy | 1,250,000 | — | — |
| 2025-03-03 | PAPADOPOULOS, STELIOS | Director | Buy | 90,000 | — | — |
| 2025-02-26 | RONA, JEFFREY A | CBFO | Sale | 3,902 | $0.56 | $2185.12 |
| 2025-02-26 | ALEXANDER, MARGARET A. | President and COO | Sale | 5,279 | $0.56 | $2956.24 |
| 2025-02-20 | RONA, JEFFREY A | CBFO | Buy | 262,500 | — | — |
| 2025-02-20 | RONA, JEFFREY A | CBFO | Buy | 43,750 | — | — |
| 2025-02-20 | LEVIN, JEREMY M | Director, CEO | Buy | 1,650,000 | — | — |
| 2025-02-20 | FRIEDMAN, BART | Director | Buy | 45,000 | — | — |
| 2025-02-20 | FITZGERALD, KEVIN JOSEPH | Director | Buy | 45,000 | — | — |
| 2025-02-20 | DUNCAN, BARBARA GAYLE | Director | Buy | 45,000 | — | — |
| 2025-02-20 | BERNSTEIN, KAREN | Director | Buy | 45,000 | — | — |
| 2025-02-20 | ALEXANDER, MARGARET A. | President and COO | Buy | 262,500 | — | — |
| 2025-02-20 | ALEXANDER, MARGARET A. | President and COO | Buy | 43,750 | — | — |
| 2025-01-27 | ALEXANDER, MARGARET A. | President and COO | Buy | 6,810 | $0.73 | $4971.30 |
| 2024-12-12 | FRIEDMAN, BART | Director | Buy | 90,000 | — | — |
| 2024-12-12 | FITZGERALD, KEVIN JOSEPH | Director | Buy | 90,000 | — | — |
| 2024-12-12 | DUNCAN, BARBARA GAYLE | Director | Buy | 90,000 | — | — |
| 2024-12-12 | BERNSTEIN, KAREN | Director | Buy | 90,000 | — | — |
| 2024-09-09 | ALEXANDER, MARGARET A. | President and COO | Buy | 140,000 | — | — |
| 2024-07-30 | RONA, JEFFREY A | CBFO | Buy | 315,000 | — | — |
| 2024-03-18 | LEVIN, JEREMY M | Director, CEO | Buy | 18,248 | $2.76 | $50364.48 |
| 2024-02-22 | TARDIO, JASON | Chief Operating Officer | Buy | 168,750 | — | — |
| 2024-02-22 | TARDIO, JASON | Chief Operating Officer | Buy | 28,125 | — | — |
| 2024-02-22 | RONA, JEFFREY A | CBFO | Buy | 168,750 | — | — |
| 2024-02-22 | RONA, JEFFREY A | CBFO | Buy | 28,125 | — | — |
| 2024-02-22 | POOLE, ROBERT MICHAEL | Director | Buy | 30,000 | — | — |
| 2024-02-22 | PERONE, THOMAS MICHAEL | General Counsel, Secretary | Buy | 168,750 | — | — |
| 2024-02-22 | PERONE, THOMAS MICHAEL | General Counsel, Secretary | Buy | 28,125 | — | — |
| 2024-02-22 | LEVIN, JEREMY M | Director, CEO | Buy | 700,000 | — | — |
| 2024-02-22 | FRIEDMAN, BART | Director | Buy | 30,000 | — | — |
| 2024-02-22 | FITZGERALD, KEVIN JOSEPH | Director | Buy | 30,000 | — | — |
| 2024-02-22 | DUNCAN, BARBARA GAYLE | Director | Buy | 30,000 | — | — |
| 2024-02-22 | BERNSTEIN, KAREN | Director | Buy | 30,000 | — | — |
| 2023-12-04 | LEVIN, JEREMY M | Director, CEO | Sale | 573,275 | — | — |
| 2023-02-23 | TARDIO, JASON | Chief Operating Officer | Buy | 175,000 | — | — |
| 2023-02-23 | RONA, JEFFREY A | CBFO | Buy | 175,000 | — | — |
| 2023-02-23 | POOLE, ROBERT MICHAEL | Director | Buy | 15,000 | — | — |
| 2023-02-23 | PERONE, THOMAS MICHAEL | General Counsel, Secretary | Buy | 175,000 | — | — |
| 2023-02-23 | LEVIN, JEREMY M | Director, CEO, 10% Owner | Buy | 600,000 | — | — |
| 2023-02-23 | FRIEDMAN, BART | Director | Buy | 15,000 | — | — |
| 2023-02-23 | FITZGERALD, KEVIN JOSEPH | Director | Buy | 15,000 | — | — |
| 2023-02-23 | DUNCAN, BARBARA GAYLE | Director | Buy | 15,000 | — | — |
| 2023-02-23 | BERNSTEIN, KAREN | Director | Buy | 15,000 | — | — |
| 2022-09-12 | TARDIO, JASON | Chief Operating Officer | Sale | 17,344 | $2.15 | $37289.60 |
| 2022-07-01 | TAKEDA, PHARMACEUTICAL CO LTD | 10% Owner | Sale | 1,250 | — | — |
| 2022-07-01 | TAKEDA, PHARMACEUTICAL CO LTD | 10% Owner | Buy | 5,750,000 | — | — |
| 2022-04-08 | TARDIO, JASON | Chief Operating Officer | Buy | 87,498 | — | — |
| 2022-04-08 | TARDIO, JASON | Chief Operating Officer | Buy | 10,000 | — | — |
| 2022-04-08 | RONA, JEFFREY A | CBFO | Buy | 194,399 | — | — |
| 2022-04-08 | RONA, JEFFREY A | CBFO | Buy | 10,000 | — | — |
| 2022-04-08 | PERONE, THOMAS MICHAEL | General Counsel, Secretary | Buy | 25,399 | — | — |
| 2022-04-08 | PERONE, THOMAS MICHAEL | General Counsel, Secretary | Buy | 10,000 | — | — |
| 2022-04-08 | LEVIN, JEREMY M | Director, CEO, 10% Owner | Buy | 423,244 | — | — |
| 2022-04-08 | FRIEDMAN, BART | Director | Buy | 69,424 | — | — |
| 2022-04-08 | DUNCAN, BARBARA GAYLE | Director | Buy | 21,347 | — | — |
| 2022-04-08 | BERNSTEIN, KAREN | Director | Buy | 69,424 | — | — |
| 2022-02-03 | TARDIO, JASON | Chief Operating Officer | Buy | 175,000 | — | — |
| 2022-02-03 | RONA, JEFFREY A | CBFO | Buy | 218,750 | — | — |
| 2022-02-03 | POOLE, ROBERT MICHAEL | Director | Buy | 15,000 | — | — |
| 2022-02-03 | PERONE, THOMAS MICHAEL | General Counsel, Secretary | Buy | 175,000 | — | — |
| 2022-02-03 | LEVIN, JEREMY M | Director, CEO, 10% Owner | Buy | 600,000 | — | — |
| 2022-02-03 | FRIEDMAN, BART | Director | Buy | 15,000 | — | — |
| 2022-02-03 | FITZGERALD, KEVIN JOSEPH | Director | Buy | 15,000 | — | — |
| 2022-02-03 | DUNCAN, BARBARA GAYLE | Director | Buy | 15,000 | — | — |
| 2022-02-03 | BERNSTEIN, KAREN | Director | Buy | 15,000 | — | — |
| 2021-10-06 | FITZGERALD, KEVIN JOSEPH | Director | Buy | 30,000 | — | — |
| 2021-07-14 | RAKHIT, AMIT | President and CMO | Buy | 34,017 | — | — |
| 2021-07-14 | RAKHIT, AMIT | President and CMO | Sale | 34,017 | $3.71 | $126203.07 |
| 2021-07-09 | POOLE, ROBERT MICHAEL | Director | Buy | 30,000 | — | — |
| 2021-07-01 | TARDIO, JASON | Chief Commercial Officer | Buy | 50,000 | — | — |
| 2021-06-11 | FRIEDMAN, BART | Director | Buy | 15,000 | — | — |
| 2021-06-11 | DUNCAN, BARBARA GAYLE | Director | Buy | 15,000 | — | — |
| 2021-06-11 | BERNSTEIN, KAREN | Director | Buy | 15,000 | — | — |
| 2021-06-02 | RONA, JEFFREY A | Chief Business Officer | Buy | 100,000 | — | — |
| 2021-05-17 | WILLIAMS, DOUGLAS E | Director | Buy | 1,750 | — | — |
Frequently asked questions
Are OVID insiders buying or selling?
Over the transactions on record, OVID insiders have been net buyers, with about $197919.68 in stock sold across 11 sales, against 6 open-market purchases.
Does insider selling at OVID mean the stock will fall?
Not by itself. Most executive selling is pre-scheduled through 10b5-1 plans filed months in advance, and insiders sell for diversification, taxes, and liquidity far more often than out of any view on the price. Insider buying is the stronger signal, especially when several insiders buy around the same time, because there is usually only one reason to put personal cash into the stock.
Which OVID insiders are selling the most?
Recent selling is concentrated in a few names. RAKHIT, AMIT accounts for the largest share on record, with about $126203.07 sold. Selling by one or two individuals matters less than broad selling across the whole leadership team, which is the pattern worth watching.